Xilio Therapeutics (XLO) Total Liabilities (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Total Liabilities data on file, last reported at $90.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 2.23% year-over-year to $90.9 million; the trailing twelve-month figure through Mar 2026 stood at $90.9 million (down 2.23% YoY), and the FY2025 full-year result was $119.4 million, up 123.3% from the prior year.
• Total Liabilities slipped to $90.9 million in Q1 2026, from $119.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $141.8 million in Q3 2025 to a low of $24.1 million in Q4 2023.
• A 5-year average of $60.1 million and a median of $53.5 million in 2024 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities declined 28.1% in 2023 and soared 164.12% in 2025, its largest moves.
• Tracing XLO's Total Liabilities over 5 years: stood at $33.5 million in 2022, then decreased by 28.1% to $24.1 million in 2023, then surged by 121.91% to $53.5 million in 2024, then surged by 123.3% to $119.4 million in 2025, then slipped by 23.84% to $90.9 million in 2026.
• Business Quant data shows XLO's Total Liabilities at $90.9 million in Q1 2026, $119.4 million in Q4 2025, and $141.8 million in Q3 2025.